Where Will AbbVie Be in 5 Years?
Most pharmaceutical businesses are slow-moving by nature due to the lengthy amount of time it takes to develop a new medicine ...
AbbVie’s Elahere wins European approval for certain ovarian cancers
The decision in Europe follows an approval granted by the US Food and Drug Administration (FDA) in March this year.
Business Insider1d
Wells Fargo Reaffirms Their Buy Rating on AbbVie (ABBV)
AbbVie (ABBV) Company Description: AbbVie, Inc. is a biopharmaceutical company focused on key therapeutic areas like immunology, oncology, neuroscience, eye care, virology, women’s health and ...
Fintel on MSN3d
Wolfe Research Initiates Coverage of AbbVie (ABBV) with Outperform Recommendation
Fintel reports that on November 15, 2024, Wolfe Research initiated coverage of AbbVie (NYSE:ABBV) with a Outperform ...
Got $1,500 to Invest? AbbVie Just Proved the Bull Thesis for Its Stock
At the start of 2023, U.S. patent exclusivity expired for the blockbuster drug Humira, AbbVie's chief cash cow. During the 20 ...
News Medical4d
Argonne receives $21.7 million to advance cancer and vaccine discoveries
Argonne National Laboratory will use its world-leading capabilities in artificial intelligence (AI) and high performance computing to research novel ways to fight cancer and transform vaccine ...
Positive Outlook on AbbVie: Geoff Meacham’s Buy Rating and Potential of Emraclidine Amid Schizophrenia Trial Challenges
AbbVie (ABBV – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Geoff Meacham ...